Contrary to this, several studies in preclinical cancer models have provided evidence that efferocytosis, mostly, but not exclusively, dependent on the TAM receptor MerTK is involved in promoting tumor progression, and several Axl, Tyro3, and MerTK targeting small molecular inhibitors are being tested in clinical trials (113). The gene discussed is MERTK; the disease is neoplasm.